➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Boehringer Ingelheim
McKinsey
Express Scripts
Harvard Business School

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 10,525,022

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,525,022
Title:Pharmaceutical composition for treating cancer, containing lactate metal salt
Abstract: The present invention relates to: a pharmaceutical composition for treating cancer containing, as an active ingredient, a metal lactate salt, which can be dissociated, in cancer cells, into lactate capable of effectively inhibiting actions such as proliferation, invasion, and metastasis of cancer cells by disturbing the metabolic processes of cancer cells; a pharmaceutical composition for inhibiting cancer metastasis; a food composition for alleviating cancer; and a method for treating cancer and a method for inhibiting cancer metastasis, both methods comprising a step of administering the lactate metal salt. The metal lactate salts of the present invention inhibits the growth of cancer cells and induces the death of cancer cells by disturbing the metabolic processes in the main energy production pathways of cancer, and inhibits the expression of factors inducing resistance against radiation exposure, while having no side effects. Therefore, the lactate metal salt can be widely utilized in a more effective anti-cancer therapy.
Inventor(s): Kim; Hwan Mook (Daejeon, KR), Jeong; Keun Yeong (Seoul, KR), Sim; Jae Jun (Seoul, KR), Jang; Yeong Su (Incheon, KR)
Assignee: METIMEDI PHARMACEUTICALS CO., LTD. (Incheon, KR)
Application Number:15/629,445
Patent Claims:see list of patent claims

Details for Patent 10,525,022

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial METIMEDI PHARMACEUTICALS CO., LTD. (Incheon, KR) 2034-12-29 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Express Scripts
McKinsey
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.